Trial reportDigestive diseases and sciences2012
Early diagnosis and treatment of postoperative endoscopic recurrence of Crohn's disease: partial benefit by infliximab--a pilot study.
Trial report in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03291743 (The Biologic Onset of Crohn's Disease), which is not on this map. Cited by 29 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives
Who cites it
29 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Infliximab for medical induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2023Pooled it
- The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis.Journal of Crohn's & colitis · 2022Pooled it
- Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.The Cochrane database of systematic reviews · 2020Pooled it
- ACG Clinical Guideline: Management of Crohn's Disease in Adults.The American journal of gastroenterology · 2018Guideline
- Managing Crohn's Disease Postoperative Recurrence Beyond Prophylaxis: A Comprehensive Review with Meta-Analysis.Biomedicines · 2024Review
- Predictive Factors of Non-Inflammatory Small Bowel Obstruction After Bowel Resection in Crohn's Patients.Gastroenterology research · 2024Article
- The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn's disease in real world-data: a retrospective study.BMC gastroenterology · 2023Article
- Review
- Prophylactic Treatment with Vedolizumab in the Prevention of Postoperative Recurrence (POR) in High-Risk Crohn's Patients.Journal of clinical medicine · 2023Article
- Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's Disease.Digestive diseases and sciences · 2021Article
- Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin.Journal of inflammation research · 2021Article
- Prophylaxis of Crohn's disease recurrence: A surgeon's perspective.Annals of gastroenterological surgery · 2020Review
- Tailored Medical Management of the Complex Postoperative Crohn's Disease Patient.Clinics in colon and rectal surgery · 2019Review
- Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.Digestive diseases and sciences · 2019Article
- Faecal calprotectin and magnetic resonance imaging in detecting Crohn's disease endoscopic postoperative recurrence.World journal of gastroenterology · 2018Observational
- Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis.Frontline gastroenterology · 2017Article
- Second Korean guidelines for the management of Crohn's disease.Intestinal research · 2017Review
- Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review.Medicine · 2016Article
- Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2016Article
- Optimal delivery of follow-up care after surgery for Crohn's disease: current perspectives.Clinical and experimental gastroenterology · 2016Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundCurrent data indicate that infliximab-given immediately after surgery-may be very effective in preventing postsurgical recurrence of Crohn's disease. However, it is unknown whether a similar benefit would result from early diagnosis and treatment, rather than prevention of endoscopic recurrence.
aimsThe primary outcome of this study was to clarify whether infliximab, given after diagnosis of postoperative endoscopic recurrence of Crohn's diseases (Rutgeerts score ≥ 2) can induce endoscopic remission (score <2) at 54 weeks. The secondary outcomes were improvement in the endoscopic score and clinical recurrence at 54 weeks.
methodsIn this prospective open label multicenter pilot study 43 patients with ileocolonic Crohn's disease subjected to curative surgery underwent colonoscopy 6 months after surgery. Patients with endoscopic recurrence (Rutgeerts score ≥2) were treated with either mesalamine 800 mg tid or infliximab 5 mg/kg bw on a maintenance basis. Colonoscopy was performed after 54 weeks of therapy.
resultsA total of 24/43 patients were diagnosed with endoscopic recurrence at 6 months. Thirteen were treated with infliximab and 11 with mesalamine. None of the 11 mesalamine-treated patients had endoscopic remission at 54 weeks. Two had clinical recurrence at 8 and 9 months. Fifty-four percent of patients treated with infliximab had endoscopic remission at 54 weeks (P = 0.01) while 69% had an improvement in the endoscopic score. None had clinical recurrence.
conclusionsTreatment of postsurgical endoscopic lesions by infliximab appears superior to mesalamine. However, a sizeable proportion of patients did not fully benefit from this strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.